ARGX vs. BNTX: argenx vs. BioNTech Stock Comparison

Company Profile

argenx (ARGX) and BioNTech (BNTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Both argenx (ARGX) and BioNTech (BNTX) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

BioNTech (BNTX) has an aggressive beta of 1.30, indicating higher sensitivity to broad-market moves, while argenx (ARGX) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

argenx (ARGX) has no ROE value reported for this period; BioNTech (BNTX) reports a negative figure of -8.14%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.

Both argenx (ARGX) at 36.27% and BioNTech (BNTX) at 30.28% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while BioNTech (BNTX) at 4.32% is closer to the peer norm — faster top-line expansion for ARGX.

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: BioNTech (BNTX) shows current ratio of 8.55 against its industry benchmark, while argenx (ARGX) has no reading this period.

Both argenx (ARGX) at 0.01 and BioNTech (BNTX) at 0.02 keep leverage in the lower quartile of their industries, with less balance-sheet debt relative to equity than most peers.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

On P/S ratio, both argenx (ARGX) at 9.86 and BioNTech (BNTX) at 8.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile relative to book while argenx (ARGX) at 172.23 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics